Drug: A-Methapred

A-Methapred (methylprednisolone sodium succinate for injection, USP) sterile powder contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone. The chemical name for methylprednisolone sodium succinate is pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxo-propoxy)-11,17-dihydroxy-6-methyl-monosodium salt, (6a, 11ß), and the molecular weight is 496.53. The structural formula is represented below: Methylprednisolone sodium succinate is so extremely soluble in water that it may be administered in a small volume of diluent and is especially well suited for intravenous use in situations in which high blood levels of methylprednisolone are required rapidly. A-Methapred (methylprednisolone sodium succinate) is available in several strengths and packages for intravenous or intramuscular administration. 40 mg Single-Dose Vial- Each mL (when mixed) contains methylprednisolone sodium succinate equivalent to 40 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.46 mg dibasic sodium phosphate anhydrous; 25 mg lactose anhydrous; 8.8 mg benzyl alcohol added as preservative. 125 mg Single-Dose Vial- Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.4 mg dibasic sodium phosphate anhydrous; 17.6 mg benzyl alcohol added as preservative. When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8 and the tonicities are, for the 40 mg per mL solution, 0.50 osmolar; for the 125 mg per 2 mL, 0.40 osmolar; (Isotonic saline = 0.28 osmolar). IMPORTANT- Use only Bacteriostatic Water For Injection with Benzyl Alcohol when reconstituting A-Methapred (methylprednisolone sodium succinate) . Use within 48 hours after mixing. Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Fluid and Electrolyte Disturbances Sodium retention, Fluid retention, Congestive heart failure in susceptible patients, Potassium loss, Hypokalemic alkalosis, Hypertension Musculoskeletal Muscle weakness, Steroid myopathy, Loss of muscle mass, Severe arthralgia, Vertebral compression fractures, Aseptic necrosis of femoral and humeral heads, Pathologic fracture of long bones, Osteoporosis Gastrointestinal Peptic ulcer with possible perforation and hemorrhage, Pancreatitis, Abdominal distention, and Ulcerative esophagitis Dermatologic Impaired wound healing, Thin fragile skin, Petechiae and ecchymoses, Facial erythema, Increased sweating, May suppress reactions to skin tests Neurological Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, Convulsions, Vertigo, Headache Endocrine Development of Cushingoid state, Suppression of growth in children, Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, Menstrual irregularities, Decreased carbohydrate tolerance, Manifestations of latent diabetes mellitus, Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts, Increased intraocular pressure, Glaucoma, Exophthalmos Metabolic Negative nitrogen balance due to protein catabolism The following additional adverse reactions are related to parenteral corticosteroid therapy: Hyperpigmentation or hypopigmentation, Subcutaneous and cutaneous atrophy, Sterile abscess, Anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, Urticaria, Nausea and vomiting, Cardiac arrhythmias; hypotension or hypertension Read the A-Methapred (methylprednisolone sodium succinate) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

When high dose therapy is desired, the recommended dose of A-Methapred (methylprednisolone sodium succinate) sterile powder is 30 mg/kg administered intravenously over at least 30 minutes. This dose may be repeated every 4 to 6 hours for 48 hours. In general, high dose corticosteroid therapy should be continued only until the patient's condition has stabilized; usually not beyond 48 to 72 hours. Although adverse effects associated with high dose short-term corticoid therapy are uncommon, peptic ulceration may occur. Prophylactic antacid therapy may be indicated. In other indications initial dosage will vary from 10 to 40 mg of methylprednisolone depending on the clinical problem being treated. The larger doses may be required for short-term management of severe, acute conditions. The initial dose usually should be given intravenously over a period of several minutes. Subsequent doses may be given intravenously or intramuscularly at intervals dictated by the patient's response and clinical condition. Corticoid therapy is an adjunct to, and not replacement for conventional therapy. Dosage may be reduced for infants and children but should be governed more by the severity of the condition and response of the patient than by age or size. It should not be less than 0.5 mg/kg every 24 hours. Dosage must be decreased or discontinued gradually when the drug has been administered for more than a few days. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. Routine laboratory studies, such as urinalysis, two-hour postprandial blood sugar, determination of blood pressure and body weight, and a chest X-ray should be made at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with an ulcer history or significant dyspepsia. A-Methapred (methylprednisolone sodium succinate) may be administered by intravenous or intramuscular injection or by intravenous infusion, the preferred method for initial emergency use being intravenous injection. To administer by intravenous (or intramuscular) injection, prepare solution as directed. The desired dose may be administered intravenously over a period of several minutes. To prepare solutions for intravenous infusion, first prepare the solution for injection as directed. This solution may then be added to indicated amounts of 5% dextrose in water, isotonic saline solution or 5% dextrose in isotonic saline solution. Multiple Sclerosis In treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone). Directions for Reconstitution
  1. Remove protective cap.
  2. Cleanse stopper with suitable germicide.
  3. Aseptically add 1 mL Bacteriostatic Water for Injection, USP (with benzyl alcohol) for the 40 mg vial or 2 mL Bacteriostatic Water for Injection, USP (with benzyl alcohol) for the 125 mg vial.
  4. Agitate to effect solution.
  5. Invert vial. Insert needle through target area of stopper until tip is just visible. Withdraw dose.
Storage Conditions Protect from light. Store unreconstituted product at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Store solution at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Use solution within 48 hours after mixing.

Source: http://www.rxlist.com

The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, A-Methapred (methylprednisolone sodium succinate) sterile powder is indicated for intravenous or intramuscular use in the following conditions:
  1. Endocrine Disorders
    • Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)
    • Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)
    • Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful
    • Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected
    • Congenital adrenal hyperplasia
    • Hypercalcemia associated with cancer
    • Nonsuppurative thyroiditis
  2. Rheumatic Disorders
    As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
    • Post-traumatic osteoarthritis
    • Synovitis of osteoarthritis
    • Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
    • Acute and subacute bursitis
    • Epicondylitis
    • Acute nonspecific tenosynovitis
    • Acute gouty arthritis
    • Psoriatic arthritis
    • Ankylosing spondylitis
  3. Collagen Diseases
    During an exacerbation or as maintenance therapy in selected cases of:
    • Systemic lupus erythematosus
    • Systemic dermatomyositis (polymyositis)
    • Acute rheumatic carditis
  4. Dermatologic Diseases
    • Pemphigus
    • Severe erythema multi-forme (Stevens-Johnson syndrome)
    • Exfoliative dermatitis
    • Bullous dermatitis herpetiformis
    • Severe seborrheic dermatitis
    • Severe psoriasis
    • Mycosis fungoides
  5. Allergic States
    Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:
    • Bronchial asthma
    • Contact dermatitis
    • Atopic dermatitis
    • Serum sickness
    • Seasonal or perennial allergic rhinitis
    • Drug hypersensitivity reactions
    • Urticarial transfusion reactions
    • Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)
  6. Ophthalmic Diseases
    Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
    • Herpes zoster ophthalmicus
    • Iritis, iridocyclitis
    • Chorioretinitis
    • Diffuse posterior uveitis and choroiditis
    • Optic neuritis
    • Sympathetic ophthalmia
    • Anterior segment inflammation
    • Allergic conjunctivitis
    • Allergic corneal marginal ulcers
    • Keratitis
  7. Gastrointestinal Diseases
    To tide the patient over a critical period of the disease in:
    • Ulcerative colitis (systemic therapy)
    • Regional enteritis (systemic therapy)
  8. Respiratory Diseases
    • Symptomatic sarcoidosis
    • Berylliosis
    • Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
    • Loeffler's syndrome not manageable by other means
    • Aspiration pneumonitis
  9. Hematologic Disorders
    • Acquired (autoimmune) hemolytic anemia
    • Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)
    • Secondary thrombocytopenia in adults
    • Erythroblastopenia (RBC anemia)
    • Congenital (erythroid) hypoplastic anemia
  10. Neoplastic Diseases
    For palliative management of:
    • Leukemias and lymphomas in adults
    • Acute leukemia of childhood
  11. Edematous States
    • To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
  12. Nervous System
    • Acute exacerbations of multiple sclerosis
  13. Miscellaneous
    • Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
    • Trichinosis with neurologic or myocardial involvement

Source: http://www.rxlist.com

The use of A-Methapred (methylprednisolone sodium succinate) sterile powder is contraindicated in premature infants because the reconstitution diluent contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants. A-Methapred (methylprednisolone sodium succinate) sterile powder is also contraindicated in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

No information provided.

Source: http://www.rxlist.com

A-Methapred (methylprednisolone sodium succinate) sterile powder is available in the following packages: List Container Concentration 3217 Single-Dose Vial 40 mg/vial 3218 Single-Dose Vial 125 mg/vial Rev: October, 2005. Hospira Inc., Lake Forest, IL 60045, USA. FDA rev date: 11/25/2008 Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Precautions Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.) Since complications of treatment with glucocorticoids are dependent on the size of the dose and duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Last reviewed on RxList: 2/13/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Women's Health Care an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically A-Methapred. Find what medications you are taking today.